PMID: 3755281Jun 1, 1986Paper

Differing response rates and survival between squamous and non-squamous non-small cell lung cancer. Comparison of CAP versus MAP

American Journal of Clinical Oncology
R T EaganJ R Jett

Abstract

One hundred and thirty patients with advanced non-small cell lung cancer were treated in a randomized study with either CAP (cyclophosphamide, doxorubicin, and cisplatin) or MAP (mitomycin C, doxorubicin, and cisplatin). Among all patients, regardless of cell type, the regression rate was slightly higher for MAP (46%) than CAP (34%) but no differences were detected in time to progression and overall survival. However, differences were apparent by treatment when patients were divided into two groups: squamous cell (SQC) and non-squamous cell (non-SQC). MAP, compared to CAP, was associated with a significantly superior regression rate (60% vs. 33%), time to progression, and overall survival in SQC. On the other hand, CAP, compared to MAP, was associated with a significantly longer overall survival in non-SQC. This apparent difference among subtypes of non-small cell lung cancer in response to chemotherapy regimens differing only in one drug, if confirmed, will need to be kept in mind in designing future studies.

Citations

Jan 1, 1991·Cancer Chemotherapy and Pharmacology·J B SørensenH H Hansen
Jun 4, 1999·Annals of Nuclear Medicine·H TakekawaY Kawakami
Jun 1, 1997·American Journal of Clinical Oncology·S H Okuno, S Frytak
Dec 11, 1990·Cancer Treatment Reviews·S A Rosenthal, W J Curran
Oct 1, 1995·The Journal of Thoracic and Cardiovascular Surgery·L E StenbygaardJ E Olsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.